Experience of the use of ixabepilone in polychemotherapy regimens for disseminated triple-negative breast cancer


DOI: https://dx.doi.org/10.18565/pharmateca.2019.12.15-18

E.V. Glazkova, M.A. Frolova, S.F. Menshikov, M.B. Stenina

N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
Therapy of disseminated triple-negative breast cancer (BC) remains an acute problem when choosing a treatment strategy. To date, there is no targeted therapy for this BC subtype that can significantly increase life expectancy. The main treatment for triple-negative BC is chemotherapy, whose reserves are limited due to the rapid development of drug resistance. Unfortunately, the efficacy of antitumor drugs shown in clinical trials is not always translated into clinical practice with comparable results of efficacy and safety. Ixabepilone, a representative of epothilones, has been shown to be effective in the treatment of triple-negative breast cancer resistant to taxanes and anthracyclines. We present our experience in the use of ixabepilone in polychemotherapy regimens for disseminated triple-negative BC.
Keywords: triple negative breast cancer, metastatic breast cancer, ixabepilon

About the Autors


Corresponding author: Elena V. Glazkova, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia; e-mail: mdglazkova@gmail.com
Address: 23, Kashirskoye Highway, Moscow 115478, Russian Federation


Бионика Медиа